Aprea therapeutics announces agreement with md anderson cancer center to explore apr-1051 as a potential treatment for head and neck squamous cell carcinoma (hnscc)

Doylestown, pa., march 11, 2025 (globe newswire) -- aprea therapeutics, inc. (nasdaq: apre) (“aprea”, or the “company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, announced today that it has entered into a material transfer agreement (mta) with md anderson cancer center. under the agreement, aprea will supply its proprietary wee1 kinase inhibitor, apr-1051, to support preclinical research aimed at exploring its potential in treating hpv+ and hpv- head and neck squamous cell carcinoma (hnscc) expressing genomic markers of replication stress.
APR Ratings Summary
APR Quant Ranking